Trial results

Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial

NCT07676331 on ClinicalTrials.gov · last registry update 2026-07-07

Registered but not yet open, with 168 participants planned. Due to report 1 March 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Ki67 proliferation marker. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Universitaire Ziekenhuizen KU Leuven

Sponsor type

Other

Enrollment

168

Started

2026-08-01

Primary completion

2028-03-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Ki67 proliferation marker

Conditions studied

Hormone-receptor-positive Breast Cancer · Early Breast Cancer

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.